Day: March 28, 2025
Positions Curium as leading manufacturer of Lu-177 isotope
Brings innovative R&D expertise and pipeline to Curium
Enhances Curium’s SPECT & PET geographical coverage and supply chainPARIS, March 28, 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.
The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates, for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval).
Monrol complements and adds to Curium’s...
Intchains Group Limited Announces Closing of Registered Direct Offering of its ADSs and Warrants
Written by Customer Service on . Posted in Public Companies.
SINGAPORE, March 27, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” “us” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and the active development of innovative Web3 applications, today announced the closing of its US$1.0 million registered direct offering.
On March 27, 2025, we closed the previously announced US$1.0 million registered direct offering for the purchase and sale of 361,011 American Depositary Shares (“ADSs”), each representing two of our Class A ordinary shares (the “Class A Ordinary Shares”), at a purchase price of US$2.77 per ADS, and warrants to purchase up to an aggregate of 361,011 ADSs at US$2.77 per ADS, which is equal to the offering price per ADS (the “Warrants”).
We received...
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Written by Customer Service on . Posted in Public Companies.
Châtillon, France, March 27, 2025
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if ApprovedDBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants
DBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA) for the Viaskin® peanut patch in children 4 – 7-years-old and commercial launch, if approved
DBV will host an investor conference call on Monday, March 31st at 5:00pm ET (23h00 CET) to discuss the financing and FDA updateDBV Technologies (the “Company” or “DBV”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT), a clinical-stage...
Prime Drink Group Announces Additional Closing of Private Placement and Provides Corrective Disclosure
Written by Customer Service on . Posted in Public Companies.
MONTREAL, March 27, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has closed an additional and final subscription with respect to its non-brokered private placement (the “Offering”) of units of the Company (each, a “Unit”) for gross proceeds of $99,960, through the issuance of 100 Units consisting of the issuance of 588,000 common shares of the Company (the “Shares”) and 588,000 common share purchase warrants (the “Warrants”). The Company raised aggregate gross proceeds of $1,910,235.60 for the entire Offering.
The securities underlying the Units issued pursuant to the second closing of the Offering are subject to resale restrictions, including a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. The...
Intercont (Cayman) Limited Announces Pricing of Its Initial Public Offering
Written by Customer Service on . Posted in Public Companies.
HONG KONG, March 27, 2025 (GLOBE NEWSWIRE) — Intercont (Cayman) Limited (“Intercont” or the “Company”), a global shipping enterprise with plans for seaborne pulping operations, today announced the pricing of its initial public offering (the “Offering”) of 1,500,000 ordinary shares (the “Ordinary Shares”), at a public offering price of $7.00 per share. The Company expects to receive total gross proceeds of $10,500,000 from the Offering, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on March 28, 2025, New York time, under the ticker symbol “NCT”.
In addition, the Company has granted the underwriters an option, within 45 days from the closing of the Offering, to purchase up to an additional 225,000...